Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19457046 | 0.85 | ALDH1A1 (0.61) | ALDH1A1TDP1L3MBTL1MAPTKDM4E | |
| SCHEMBL7416930 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TDP1L3MBTL1MAPTKDM4E | |
| SCHEMBL29394371 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TDP1L3MBTL1MAPTKDM4E | |
| SCHEMBL22589779 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TDP1L3MBTL1MAPTKDM4E | |
| SCHEMBL272154 | 0.81 | ERN1 (0.57) | ALDH1A1TDP1MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL7995969 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TDP1L3MBTL1MAPTHPGD | |
| SCHEMBL7995971 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TDP1L3MBTL1MAPTHPGD | |
| SCHEMBL10645648 | 0.79 | ALDH1A1 (0.51) | ALDH1A1TDP1L3MBTL1MAPTKDM4E | |
| SCHEMBL170690 | 0.79 | ERN1 (0.55) | ALDH1A1TDP1MAPTKDM4ECYP3A4 | |
| SCHEMBL215837 | 0.79 | TDP1 (0.67) | ALDH1A1TDP1L3MBTL1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384751-B2 | Allosteric activators of the ALPHA1A-adrenergic receptor | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3958851-B1 | ALLOSTERIC ACTIVATORS OF THE ALPHA IA-ADRENERGIC RECEPTOR | CLEVELAND CLINIC FOUND (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20220227717-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA1A-ADRENERGIC RECEPTOR | THE CLEVELAND CLINIC FOUNDATION | 2022-07-21 | — | — | US | disclosed |
| EP-3958851-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA IA-ADRENERGIC RECEPTOR | The Cleveland Clinic Foundation (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020219720-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA1A -ADRENERGIC RECEPTOR | THE CLEVELAND CLINIC FOUNDATION (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2001044185-A1 | CARBON MONOXIDE-BASED SYNTHESIS OF SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| US-4448971-A | Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1984-05-15 | — | — | US | disclosed |
| US-4407811-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4399296-A | TRIMETHYLSILYL CYANOHYDRIN INTERMEDIATES | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4367234-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384751-B2 | Allosteric activators of the ALPHA1A-adrenergic receptor | ADRA1A, ADRB1, ADRA1D | ALDH1A1 145/4885TDP1 987/4885L3MBTL1 1740/4885 |
| US-20220227717-A1 | ALLOSTERIC ACTIVATORS OF THE ALPHA1A-ADRENERGIC RECEPTOR | ADRA1A, ADRB1, ADRA1D | ALDH1A1 145/4885TDP1 987/4885L3MBTL1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.